Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The RECOVERY trial, which discovered four effective treatments for COVID-19, has expanded to investigate treatments for influenza (flu).

Pills packages of different types and colours © spring23/ Shutterstock

Globally, seasonal flu epidemics are estimated to kill between 290,000 and 650,000 people every year. Despite having known about influenza for almost a century and knowing that pandemic influenza remains one of the greatest threats to human health, we still do not have effective drugs for treating people with severe influenza.

Until now, few large-scale clinical trials have evaluated treatments for patients hospitalised with influenza. However, the features of the RECOVERY trial that made it such a success against COVID-19 – including its streamlined design, large scale, and practical integration into routine healthcare – make it well-placed to also improve the care of severe influenza patients.

Sir Peter Horby, Moh Family Foundation Professor of Emerging Infectious and Global Health in the Nuffield Department of Medicine, University of Oxford, and Joint Chief Investigator for the RECOVERY trial, said ‘As well as being the greatest pandemic risk, influenza remains a serious annual scourge. In a bad year, as many as 25,000 people in the UK die as a result of influenza.

Read the full story on the University of Oxford website.

Similar stories

New small molecule found to suppress the evolution of antibiotic resistance in bacteria

Researchers from the Ineos Oxford Institute for antimicrobial research (IOI) and the Department of Pharmacology at Oxford University, have developed a new small molecule that can suppress the evolution of antibiotic resistance in bacteria and make resistant bacteria more susceptible to antibiotics.